TLPO Vaccine (Elios Therapeutics/LumaBridge)

N/A

Report date: 2024/01/09 09:21:43

Base Information

Drug NameTLPO Vaccine (Elios Therapeutics/LumaBridge)

Drug Alias NameParticle Only (TLPO) Cancer Vaccine(Elios Therapeutics/LumaBridge)肿瘤裂解物颗粒负载疫苗Tumour lysate particle only vaccine (Elios Therapeutics/LumaBridge)

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisMelanoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesOrbis Health Solutions

China Registration ClassN/A

Develop Information

Active CompaniesElios Therapeutics Llc

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsSolid tumoursNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A